EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Evaluation of [155/161Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours

Luke Wharton iD, Scott W McNeil iD, Helen Merkens, Zheliang Yuan iD, Michiel Van de Voorde iD, Gokce Engudar, Aidan Ingham iD, Helena Koniar iD, Cristina Rodríguez-Rodríguez iD, Valery Radchenko, Maarten Ooms iD, Peter Kunz und 3 weitere

Molecules · 2023

DOI: 10.3390/molecules28073155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Luke Wharton und 14 weiteren Autor:innen. Beteiligte Einrichtung: Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada. Hauptthemen laut MEDLINE: Neuroendocrine Tumors. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council, Neuroendocrine Tumor Research Foundation, NSERC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Terbium radioisotopes (149Tb, 152Tb, 155Tb, 161Tb) offer a unique class of radionuclides which encompass all four medicinally relevant nuclear decay modalities (α, β+, γ, β−/e−), and show high potential for the development of element-matched theranostic radiopharmaceuticals. The goal of this study was to design, synthesise, and evaluate the suitability of crown-TATE as a new peptide-conjugate for radiolabelling of [155Tb]Tb3+ and [161Tb]Tb3+, and to assess the imaging and pharmacokinetic properties of each radiotracer in tumour-bearing mice. [155Tb]Tb-crown-TATE and [161Tb]Tb-crown-TATE were prepared efficiently under mild conditions, and exhibited excellent stability in human serum (>99.5% RCP over 7 days). Longitudinal SPECT/CT images were acquired for 155Tb- and 161Tb- labelled crown-TATE in male NRG mice bearing AR42J tumours. The radiotracers, [155Tb]Tb-crown-TATE and [161Tb]Tb-crown-TATE, showed high tumour targeting (32.6 and 30.0 %ID/g, respectively) and minimal retention in non-target organs at 2.5 h post-administration. Biodistribution studies confirmed the SPECT/CT results, showing high tumour uptake (38.7 ± 8.0 %ID/g and 38.5 ± 3.5 %ID/g, respectively) and favourable tumour-to-background ratios. Blocking studies further confirmed SSTR2-specific tumour accumulation. Overall, these findings suggest that crown-TATE has great potential for element-matched molecular imaging and radionuclide therapy using 155Tb and 161Tb.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsMaleHumansMiceAnimalsPrecision MedicineTissue DistributionTomography, Emission-Computed, Single-PhotonRadioisotopesRadiopharmaceuticals

Stichwörter der Autor:innen

NETsPRRTSPECT imagingTerbium-155Terbium-161theranostics

Substanzen

RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.
  • Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
  • Nuclear Medicine Applications, Belgium Nuclear Research Center (SCK CEN), Boeretang, 200, 2400 Mol, Belgium.
  • Department of Physics and Astronomy, University of British Columbia, 6224 Agronomy Road, Vancouver, BC V6T 1Z1, Canada.
  • Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
  • Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.

ORCID-Profile: Luke Wharton, Scott W McNeil, Zheliang Yuan, Michiel Van de Voorde, Aidan Ingham, Helena Koniar, Cristina Rodríguez-Rodríguez, Maarten Ooms, François Bénard, Paul Schaffer, Hua Yang

Förderung

  • Natural Sciences and Engineering Research Council
  • Neuroendocrine Tumor Research Foundation
  • NSERC
  • NETRF
  • Canada Foundation for Innovation
  • TRIUMF

Zitieren

APA

Wharton, L., McNeil, S. W., Merkens, H., Yuan, Z., Van de Voorde, M., Engudar, G., Ingham, A., Koniar, H., Rodríguez-Rodríguez, C., Radchenko, V., Ooms, M., Kunz, P., Bénard, F., Schaffer, P., & Yang, H. (2023). Preclinical Evaluation of [155/161Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours. Molecules. https://doi.org/10.3390/molecules28073155

Vancouver

Wharton L, McNeil SW, Merkens H, Yuan Z, Van de Voorde M, Engudar G, et al. Preclinical Evaluation of [155/161Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours. Molecules. 2023. doi:10.3390/molecules28073155

BibTeX
@article{Wharton2023,
  author = {Wharton, Luke and McNeil, Scott W and Merkens, Helen and Yuan, Zheliang and Van de Voorde, Michiel and Engudar, Gokce and Ingham, Aidan and Koniar, Helena and Rodríguez-Rodríguez, Cristina and Radchenko, Valery and Ooms, Maarten and Kunz, Peter and Bénard, François and Schaffer, Paul and Yang, Hua},
  title = {Preclinical Evaluation of [155/161Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28073155}
}
Kostenlos starten →